Ronda Copher

1.1k total citations
51 papers, 809 citations indexed

About

Ronda Copher is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Ronda Copher has authored 51 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Hematology and 10 papers in Genetics. Recurrent topics in Ronda Copher's work include Cancer Treatment and Pharmacology (10 papers), Acute Myeloid Leukemia Research (9 papers) and Economic and Financial Impacts of Cancer (6 papers). Ronda Copher is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Acute Myeloid Leukemia Research (9 papers) and Economic and Financial Impacts of Cancer (6 papers). Ronda Copher collaborates with scholars based in United States, Australia and Japan. Ronda Copher's co-authors include Ross Macmillan, Michael S. Broder, Joyce A. Cramer, Dasha Cherepanov, Eunice Chang, Annette Powers, Bong-Chul Chu, Jay Margolis, José E Cavazos and Claudio Faria and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Ronda Copher

47 papers receiving 775 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronda Copher United States 12 262 239 129 119 118 51 809
Suzanne Wait France 21 112 0.4× 134 0.6× 177 1.4× 79 0.7× 31 0.3× 46 1.3k
Christine Olsen United States 18 145 0.6× 36 0.2× 416 3.2× 348 2.9× 29 0.2× 36 1.3k
Inge Varekamp Netherlands 18 63 0.2× 68 0.3× 34 0.3× 60 0.5× 71 0.6× 30 1.1k
Abhik Bhattacharya United States 16 227 0.9× 171 0.7× 169 1.3× 122 1.0× 21 0.2× 48 1.1k
Mine Özkan Türkiye 12 45 0.2× 107 0.4× 165 1.3× 46 0.4× 65 0.6× 41 651
Lisa Brunton United Kingdom 19 49 0.2× 86 0.4× 477 3.7× 178 1.5× 104 0.9× 35 1.2k
Anne Mette Tranberg Kejs Denmark 14 104 0.4× 186 0.8× 251 1.9× 113 0.9× 75 0.6× 27 674
Janet Lee United States 15 98 0.4× 200 0.8× 20 0.2× 52 0.4× 66 0.6× 38 767
AnnMarie Groarke Ireland 20 101 0.4× 241 1.0× 358 2.8× 123 1.0× 169 1.4× 40 978
Gary M. Clark United States 17 26 0.1× 188 0.8× 487 3.8× 312 2.6× 143 1.2× 40 1.6k

Countries citing papers authored by Ronda Copher

Since Specialization
Citations

This map shows the geographic impact of Ronda Copher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronda Copher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronda Copher more than expected).

Fields of papers citing papers by Ronda Copher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronda Copher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronda Copher. The network helps show where Ronda Copher may publish in the future.

Co-authorship network of co-authors of Ronda Copher

This figure shows the co-authorship network connecting the top 25 collaborators of Ronda Copher. A scholar is included among the top collaborators of Ronda Copher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronda Copher. Ronda Copher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Klink, Andrew J., Ajeet Gajra, Russell L. Knoth, et al.. (2022). Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia. Leukemia Research. 122. 106946–106946. 1 indexed citations
4.
Kobayashi, Masahiro, Masatoshi Kudo, Namiki Izumi, et al.. (2019). Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. Journal of Gastroenterology. 54(6). 558–570. 59 indexed citations
5.
Adejoro, Oluwakayode, et al.. (2019). Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States. Advances in Therapy. 36(4). 896–915. 16 indexed citations
6.
Hudgens, Stacie, Ronda Copher, & Genevieve Meier. (2018). Longitudinal Analysis Of Adjusted EQ-5D Utility Score At Baseline, Progression-Free Survival, And Progression For Lenvatinib Versus Sorafenib. Value in Health. 21. S35–S35. 1 indexed citations
7.
Hudgens, Stacie, Ronda Copher, & Genevieve Meier. (2018). Evaluation Of The Disease-Specific Items On The Eortc In Hepatocellular Carcinoma Patients Treated With Lenvatinib Or Sorafenib. Value in Health. 21. S37–S37. 1 indexed citations
8.
Bentley, Tanya G. K., Joshua T. Cohen, Elena B. Elkin, et al.. (2017). Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs. Value in Health. 20(2). 200–205. 31 indexed citations
9.
Mukherjea, Arnab, et al.. (2016). A Novel Method for Evaluating Value Assessment Frameworks. Value in Health. 19(7). A376–A376.
10.
11.
Tremblay, Gabriel, et al.. (2016). Cost-Effectiveness Analysis of Lenvatinib as a Treatment for Radioactive Iodine Refractory Differentiated Thyroid Cancer in the United States. Value in Health. 19(3). A151–A151. 4 indexed citations
12.
Copher, Ronda, et al.. (2015). Indirect Costs Among Metastatic Breast Cancer Patients Receiving Eribulin. Value in Health. 18(3). A202–A202. 1 indexed citations
13.
Cramer, Joyce A., et al.. (2015). Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. Epilepsy & Behavior. 44. 40–46. 9 indexed citations
14.
Cramer, Joyce A., Eunice Chang, Annette Powers, et al.. (2014). Healthcare utilization and costs in children with stable and uncontrolled epilepsy. Epilepsy & Behavior. 32. 135–141. 49 indexed citations
15.
DiBonaventura, Marco, et al.. (2014). The Association Between Non-Adherence and Quality of Life Among Women with Metastatic Breast Cancer. Value in Health. 17(3). A92–A92. 1 indexed citations
16.
DiBonaventura, Marco, et al.. (2014). Patient Preferences Of Treatments Among Women With Metastatic Breast Cancer: Results From A Conjoint Analysis Study. Value in Health. 17(3). A4–A4. 1 indexed citations
17.
Cramer, Joyce A., Eunice Chang, Annette Powers, et al.. (2013). Healthcare utilization and costs in adults with stable and uncontrolled epilepsy. Epilepsy & Behavior. 31. 356–362. 122 indexed citations
18.
Copher, Ronda, et al.. (2012). Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. Journal of Medical Economics. 15(5). 947–955. 48 indexed citations
19.
Copher, Ronda, et al.. (2012). Retrospective analysis of variation in heavy menstrual bleeding treatments by age and underlying cause. Current Medical Research and Opinion. 29(2). 127–139. 7 indexed citations
20.
Pocoski, Jennifer, et al.. (2011). PIH40 RETROSPECTIVE DATABASE ANALYSIS OF TREATMENT PATTERNS AND HEALTH CARE COSTS AMONG WOMEN WITH IDIOPATHIC HEAVY MENSTRUAL BLEEDING. Value in Health. 14(3). A112–A112. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzanne Wait Breakdown of academic impact, for papers by Christine Olsen Breakdown of academic impact, for papers by Inge Varekamp Breakdown of academic impact, for papers by Abhik Bhattacharya Breakdown of academic impact, for papers by Mine Özkan Breakdown of academic impact, for papers by Lisa Brunton Breakdown of academic impact, for papers by Anne Mette Tranberg Kejs Breakdown of academic impact, for papers by Janet Lee Breakdown of academic impact, for papers by AnnMarie Groarke Breakdown of academic impact, for papers by Gary M. Clark
Rankless by CCL
2026